Summit Therapeutics plc Stock News

Cambridge, Massachusetts, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on

Cambridge, MA, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Kenneth A. Clark, JD, has been appointed to our Board of Directors, effective immediately

SAN DIEGO, Oct. 2, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of the federal securities laws by Summit Therapeutics Inc. ("Summit" or th

New York, New York--(Newsfile Corp. - October 1, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such inves

Cambridge, Massachusetts, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) is today displaying an important ePoster at IDWeek 2021. IDWeek

Summit Therapeutics Inc (NASDAQ: SMMT) announced that the FDA disagrees with its proposed change to the primary endpoint in Phase 3 Ri-CoDIFy studies. In a regulatory filing, the Company said that t

Cambridge, Massachusetts, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its

Data Additionally include Potential Benefit for the Control of Antimicrobial Resistance and a Novel Mechanism of Action Data Additionally include Potential Benefit for the Control of Antimicrobial Res

Summit Therapeutics PLC (SMMT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pr

The stock price of Summit Therapeutics Inc (NASDAQ: SMMT) increased by 26.62% today. This is why it The post Summit Therapeutics (SMMT): 26.62% Increase Explanation appeared first on Pulse 2.0.

Find out why investors are more excited than ever about these two businesses.

Cambridge, MA, May 17, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2021.

Cambridge, MA, May 12, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today the successful closing of its fully subscribed rights offering and the associated results.

CEO Robert R. Duggan continues to aggressively buy shares and expand his ownership of the company.